Leukemia Clinical Trial
Official title:
Proteomic Signature Associated With Clinical Response to Cytarabine Based Induction Therapy in Patients With AML 56 Years and Older
RATIONALE: Studying samples of blood and tissue from patients with cancer treated with
cytarabine in the laboratory may help doctors learn more about the effects of cytarabine on
cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research trial studies biomarkers associated with response to cytarabine in
samples from older patients with acute myeloid leukemia.
OBJECTIVES:
- Refinement and testing of a multiparameter flow cytometry-based cell-signaling
signature (FC classifier) associated with in vivo likelihood of complete response (CR)
to cytarabine-based induction chemotherapy in elderly patients (56 years and older)
newly diagnosed with non-M3 acute myeloid leukemia (AML).
- Identification of cell-signaling signature(s) associated with continuous CR to
cytarabine-based induction chemotherapy at one year (CCR1) in adult patients 56 years
and older with a newly diagnosed non-M3 AML.
- Identification of cell-signaling signature(s) associated with relapse-free survival at
one year (RFS1) in adult patients 56 years and older with a newly diagnosed non-M3 AML
who received cytarabine-based induction chemotherapy and achieved CR.
- To investigate changes in cell-signaling signature(s) between matched pre- and
post-treatment specimens of relapsed/refractory patients.
OUTLINE: This is a multicenter study.
Cryopreserved specimens are incubated with cytokines (e.g., interleukins), growth factors
(e.g., sargramostim or filgrastim), and chemotherapeutic agent (e.g., cytarabine, etoposide)
and other modulators. Cells are then fixed, permeabilized, and stained with antibodies that
recognize extracellular markers (for example, surface phenotypic markers such as clusters of
differentiation, drug transporters, and receptors) in conjunction with intracellular
activation-state-specific epitopes of designated signaling molecules. Subsequently, cell are
analyzed by phospho-flow cytometry (FC) in a random manner (without knowledge of clinical
variables and outcomes) to a training set (complete pre-specified FC) versus a testing set.
Cells are also analyzed by proteomic assays. Results are then compared with individual
patient scores, including predicted clinical outcomes.
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |